Welcome to our dedicated page for Serina Therapeutics news (Ticker: ser), a resource for investors and traders seeking the latest updates and insights on Serina Therapeutics stock.
Serina Therapeutics Inc (SER) is a clinical-stage biotechnology innovator advancing neurological and pain therapies through its proprietary POZ Platform technology. This page serves as the definitive source for official company announcements, research milestones, and financial updates.
Investors and industry observers will find timely updates on clinical trial progress, regulatory developments, and strategic partnerships. Our curated collection includes press releases on drug candidate advancements, peer-reviewed research findings, and executive commentary – all essential for understanding SER's position in biopharmaceutical innovation.
Key focus areas include updates on the POZ Platform's application in drug delivery systems, trial phase transitions, and collaborative research initiatives. Content is organized to provide clear context about how each development aligns with the company's mission to improve neurological and pain management therapies.
Bookmark this page for direct access to primary source materials from Serina Therapeutics. Check regularly for new insights into the company's scientific advancements and operational milestones in the competitive biotech landscape.
Serina Therapeutics (NYSE American: SER) reported third quarter 2025 results and program updates on November 13, 2025. Key regulatory news: the FDA supported a 505(b)(2) pathway and recognized the Phase 1b as registrational for SER-252, but on Nov 3, 2025 placed the IND on clinical hold pending additional information about a formulation excipient; Serina expects formal FDA communication within 30 days.
Financing and liquidity: secured a convertible note/warrant financing providing up to $20.0M with $5.0M drawn; an ATM program has generated $2.8M net proceeds; cash and cash equivalents were $8.6M at Sept 30, 2025.
Serina Therapeutics (NYSE: SER) announced on November 3, 2025 that the FDA has placed a clinical hold on the IND for SER-252, its lead program for advanced Parkinson’s disease, while requesting additional information about a commonly used formulation excipient.
Serina said the FDA feedback does not relate to the active drug substance or mechanism of action, expects the formal clinical‑hold letter within 30 days, and will work expeditiously with the FDA to resolve the request. The company reiterated prior FDA support for a 505(b)(2) NDA pathway and noted ongoing advancement of its broader POZ Platform pipeline.
Serina Therapeutics (NYSE: SER) launched an enhanced corporate communications platform on October 8, 2025 to deliver timely, transparent updates to patients, clinicians, investors, and the scientific community. The platform will offer regular digital updates, educational resources, multimedia content (including a podcast), expert commentary, webinars, and online forums to support engagement.
Serina said the initiative will coincide with preparations to initiate the planned registrational study of SER-252 in Parkinson’s disease. The SER-252-1b trial is a randomized, double-blind, placebo-controlled Phase 1b with single-ascending-dose (five cohorts of eight; n=40) and multiple-ascending-dose components (up to three cohorts of 16; n=48), conducted in the U.S. and Australia to evaluate safety, tolerability, and pharmacokinetics with exploratory efficacy measures.
Serina Therapeutics (NYSE: SER) drew the first $5 million tranche under a financing agreement that can provide up to $20 million tied to development milestones. The company submitted an IND to the FDA and received a first HREC approval in Australia.
Serina remains on track to initiate a registrational Phase 1b study of SER-252 in Q4 2025 with first patient dosing expected before year‑end. The SER-252-1b trial is randomized, double‑blind, placebo‑controlled with single‑ascending‑dose (five cohorts of eight; n=40) and multiple‑ascending‑dose components (up to three cohorts of 16; n=48), evaluating safety, tolerability, and pharmacokinetics, plus exploratory MDS‑UPDRS motor assessments across U.S. and Australian sites.
Serina Therapeutics (NYSE American: SER) has secured access to up to $20 million in financing through a convertible note agreement to advance its SER-252 clinical program for advanced Parkinson's disease. The funding, led by Board Director Greg Bailey, includes five tranches tied to clinical milestones and features 100% warrant coverage that could provide an additional $20 million if exercised.
The convertible notes have a 5-year maturity, 10% annual interest rate, and are convertible at $5.18 per share. The company plans to submit its U.S. IND application in Q4 2025 and begin patient dosing in Australia as part of its global registrational program. The SER-252-1b study is designed as a randomized, double-blind, placebo-controlled Phase 1b trial evaluating safety, tolerability, and pharmacokinetics in Parkinson's patients.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company focused on its POZ Platform™ drug optimization technology, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. CEO Steve Ledger will deliver a presentation on September 8, 2025, at 9:30 a.m. ET in New York.
The presentation will be available via live webcast for registered attendees, with an on-demand replay accessible for 90 days after the event.
Serina Therapeutics (NYSE American: SER) received positive FDA feedback supporting the advancement of SER-252, their POZ-enabled apomorphine treatment for advanced Parkinson's disease, through a 505(b)(2) NDA pathway. The company plans to initiate a registrational clinical study program with a comprehensive development strategy.
Key upcoming milestones include U.S. IND submission in Q4 2025, patient dosing in Australia in Q4 2025, and U.S. enrollment beginning in Q1 2026. The registrational study, SER-252-1b, is designed as a randomized, double-blind, placebo-controlled Phase 1b trial, evaluating safety, tolerability, and pharmacokinetics in Parkinson's disease patients with motor fluctuations.
Serina Therapeutics (NYSE American: SER) reported its Q2 2025 financial results and business updates. The company recorded a net loss of $6.4 million ($0.66 per share) compared to net income of $5.2 million in Q2 2024. Revenue increased to $130,000 from $51,000 year-over-year.
Key developments include the advancement of SER-270, a once-weekly injectable therapy for tardive dyskinesia, the appointment of Dr. Stephen Brannan to the Board, and securing $5 million in funding for SER-252 development. The company raised $1.2 million through ATM offerings and ended Q2 with $6.0 million in cash, expected to fund operations into Q4 2025.
Operating expenses increased to $5.7 million, with R&D expenses doubling to $3.2 million year-over-year. The company's lead candidate SER-252 for advanced Parkinson's disease is scheduled to enter clinical trials in Q4 2025.
Serina Therapeutics (NYSE:SER) announced the advancement of SER-270 (POZ-VMAT2i), a novel once-weekly injectable VMAT2 inhibitor for treating tardive dyskinesia (TD). The drug leverages Serina's proprietary POZ Platform™ technology to provide a long-acting alternative to daily oral medications.
The U.S. TD market, which exceeded $3.7 billion in sales in 2024, is projected to reach $5.4 billion by 2030. Currently, fewer than 30% of U.S. TD patients are diagnosed, with less than half receiving treatment. The company also plans to explore the drug's potential for treating chorea associated with Huntington's disease.
POZ-VMAT2i specifically targets underserved patients who struggle with daily medication adherence, institutionalized patients, and those with dysphagia, offering a potentially transformative solution in the VMAT2 inhibitor market.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company focused on its proprietary POZ Platform™ drug optimization technology, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference. CEO Steve Ledger will engage in a fireside chat on Tuesday, July 29, 2025, at 2:00 p.m. ET during the two-day conference scheduled for July 29-30, 2025.
FAQ
What is the current stock price of Serina Therapeutics (ser)?
What is the market cap of Serina Therapeutics (ser)?
